All lobbying filings
TARPLIN, DOWNS & YOUNG, LLC
Lobbying for BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL)
Filing · LD-2 quarterly report
Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Income
$40,000
What the client paid this registrant for the period.
Client based in
District of Columbia
Lobbyists on this filing
6
-
RAISSA H DOWNSPreviously held: Prin. Dep. Asst. Sec. for Leg. - HHS; Dep. Asst. Sec. for Leg. - HHS; Staff Dir., Sub. Cmte. on Employment, Sen. HELP Cmte.
-
JENNIFER B YOUNGPreviously held: Asst. Sec. for Leg. - HHS; Dep. Asst. Sec. for Leg. - HHS; Cmte. Staff, House Cmte. on Ways and Means; Cmte. Staff, Sen. Cmte. on Finance
-
ELIZABETH T MURRAYPreviously held: Senior Policy Advisor, Democratic Whip Steny Hoyer; Legislative Asst. for Rep. Mike Thompson, Rep. Bob Matsui, and Senator Bob Graham
-
PAMELA SMITHPreviously held: Leg. Dir., Sen. Tom Harkin; Dep. Staff Dir., Senate HELP Cmte; Staff Dir., Senate HELP Cmte; Counselor to the Asst. AG, Civil Div., Dept of Justice; Spec Counsel, Ofc of Leg. Affairs, Dept of Justice; Counsel and LA, Senator Carol Moseley-Braun
-
MARGARET JOSEPHPreviously held: CoS for Sen. Kyrsten Sinema, CoS for Rep. Kyrsten Sinema, CoS for Rep. Bobby Bright, CoS for Rep. Jim Matheson, Clerk for House Rules Cmte.
-
JEFF RECZEK New on this filingPreviously held: Dir. CDC Washington, Professional Staff Sen. Appropriations Cmte, Program Examiner OMB, Program Analyst Dept. of Transportation
Government bodies contacted
4
Lobbying activity
2
H.R. 8646, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 H.R. 9620, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 Issues pertaining to NIH & FDA funding
S. 4612/H.R. 9000 - the SCREEN For T1D Act S. 8270/H.R. 8018 - the ISLET Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to Special Diabetes Program Issues pertaining to FDA modernization